Christopher Galletta - 13 Dec 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Controller and Principal Accounting Officer
Signature
/s/ Christopher Galletta
Issuer symbol
TRVI
Transactions as of
13 Dec 2024
Net transactions value
+$7,665
Form type
4
Filing time
17 Dec 2024, 16:30:03 UTC
Previous filing
16 Feb 2024
Next filing
20 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $7,665 +15,000 +304% $0.5110 19,935 13 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -15,000 -43% $0.000000 20,000 13 Dec 2024 Common Stock 15,000 $0.5110 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,935 shares purchased through the Issuer's employee stock purchase plan.
F2 This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

Remarks:

Controller and Principal Accounting Officer